HCPCS Level II code G0465 covers the use of autologous platelet rich plasma (PRP) or other blood-derived products for treatment of diabetic chronic wounds and ulcers when delivered with an FDA-cleared device. This code is significant nationally as diabetic foot ulcers and chronic wounds are high-cost, high-utilization conditions where advanced biologic therapies may affect healing time, downstream complications, and overall episode costs. Payers use this code to identify and manage claims for device-cleared, per-treatment PRP wound therapies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for PRP in diabetic wounds, payer coverage patterns and benchmarking (when available), common billing considerations, and policy updates relevant to device-cleared blood-derived product therapies. The publication outlines service settings where G0465 is typically billed and summarizes what constitutes an included per-treatment bundle under the code description.

This briefing is written for a national audience and is intended to clarify code intent, sites of service, and the type of service activity captured by G0465, enabling payers, providers, and policy stakeholders to align documentation and claim submission practices.